Needham & Company LLC reissued their buy rating on shares of I-Mab (NASDAQ:IMAB - Free Report) in a report issued on Friday,Benzinga reports. Needham & Company LLC currently has a $4.00 target price on the stock.
Separately, Brookline Capital Management upgraded shares of I-Mab to a "strong-buy" rating in a report on Thursday, February 27th.
Read Our Latest Stock Analysis on I-Mab
I-Mab Stock Down 2.2 %
Shares of IMAB traded down $0.02 during midday trading on Friday, reaching $0.67. The stock had a trading volume of 135,824 shares, compared to its average volume of 309,699. The firm's 50 day moving average price is $0.88 and its 200-day moving average price is $1.02. I-Mab has a 52 week low of $0.60 and a 52 week high of $2.00.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in IMAB. Millennium Management LLC grew its position in I-Mab by 763.1% during the 4th quarter. Millennium Management LLC now owns 97,749 shares of the company's stock worth $83,000 after purchasing an additional 86,424 shares in the last quarter. Cantor Fitzgerald L. P. acquired a new stake in shares of I-Mab in the fourth quarter worth $119,000. BNP Paribas Financial Markets acquired a new position in I-Mab during the fourth quarter valued at $93,000. XTX Topco Ltd lifted its stake in I-Mab by 140.8% in the 3rd quarter. XTX Topco Ltd now owns 43,039 shares of the company's stock worth $53,000 after acquiring an additional 25,163 shares in the last quarter. Finally, Garden State Investment Advisory Services LLC purchased a new stake in I-Mab in the 3rd quarter worth about $179,000. 38.38% of the stock is owned by hedge funds and other institutional investors.
About I-Mab
(
Get Free Report)
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.
Read More
Before you consider I-Mab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and I-Mab wasn't on the list.
While I-Mab currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
